ships with pharmaceutical and skin care companies. Pharmaceuticals are becoming more costly due to increasingly smaller (personalized) markets (e.g. Glybera at $1.6M per treatment) -- Hence the prospect of Androcyte therapies that apply to every person (with access to reasonable health care) is a opportu

ships with pharmaceutica= and skin care companies. Pharmaceuticals are becoming more costly du= to increasingly smaller (personalized) markets (e.g. Glybera at $1.6M per =reatment) -- Hence the prospect of Androcyte therapies that apply to every =erson (with access to reasonable health care) is a opport